Neuca S.A. (NEU) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.074x

Based on the latest financial reports, Neuca S.A. (NEU) has a cash flow conversion efficiency ratio of 0.074x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł89.73 Million ≈ $24.70 Million USD) by net assets (zł1.21 Billion ≈ $333.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Neuca S.A. - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Neuca S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Neuca S.A. (NEU) total liabilities for a breakdown of total debt and financial obligations.

Neuca S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neuca S.A. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Bain Capital Specialty Finance Inc
NYSE:BCSF
0.008x
Sgis Songshan Co Ltd
SHE:000717
0.079x
Hengsheng Energy Co Ltd
SHG:605580
0.057x
Zhejiang Zanyu Technology Co Ltd
SHE:002637
0.028x
New Huadu Supercenter Co Ltd
SHE:002264
0.016x
IPERIONX LTD SP.ADR/10
F:30Z0
N/A
Huadian Power International Corporation Limited
F:SHX
0.013x
SHANDONG HI-SP.G.HD-0001
F:HRI
N/A

Annual Cash Flow Conversion Efficiency for Neuca S.A. (2005–2024)

The table below shows the annual cash flow conversion efficiency of Neuca S.A. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see Neuca S.A. market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 zł1.41 Billion
≈ $388.53 Million
zł63.23 Million
≈ $17.40 Million
0.045x -83.57%
2023-12-31 zł1.06 Billion
≈ $290.96 Million
zł288.27 Million
≈ $79.34 Million
0.273x -24.47%
2022-12-31 zł930.54 Million
≈ $256.10 Million
zł335.94 Million
≈ $92.45 Million
0.361x +6.41%
2021-12-31 zł884.81 Million
≈ $243.51 Million
zł300.20 Million
≈ $82.62 Million
0.339x -18.82%
2020-12-31 zł776.80 Million
≈ $213.79 Million
zł324.67 Million
≈ $89.35 Million
0.418x +33.42%
2019-12-31 zł645.62 Million
≈ $177.68 Million
zł202.25 Million
≈ $55.66 Million
0.313x +68.25%
2018-12-31 zł654.89 Million
≈ $180.23 Million
zł121.94 Million
≈ $33.56 Million
0.186x -0.34%
2017-12-31 zł651.72 Million
≈ $179.36 Million
zł121.76 Million
≈ $33.51 Million
0.187x -37.29%
2016-12-31 zł587.58 Million
≈ $161.71 Million
zł175.05 Million
≈ $48.18 Million
0.298x -12.78%
2015-12-31 zł528.19 Million
≈ $145.37 Million
zł180.40 Million
≈ $49.65 Million
0.342x -21.18%
2014-12-31 zł467.42 Million
≈ $128.64 Million
zł202.56 Million
≈ $55.75 Million
0.433x +542.54%
2013-12-31 zł410.66 Million
≈ $113.02 Million
zł27.70 Million
≈ $7.62 Million
0.067x -81.52%
2012-12-31 zł342.21 Million
≈ $94.18 Million
zł124.92 Million
≈ $34.38 Million
0.365x -36.95%
2011-12-31 zł286.86 Million
≈ $78.95 Million
zł166.08 Million
≈ $45.71 Million
0.579x +898.50%
2010-12-31 zł243.37 Million
≈ $66.98 Million
zł14.11 Million
≈ $3.88 Million
0.058x -73.53%
2009-12-31 zł223.67 Million
≈ $61.56 Million
zł48.99 Million
≈ $13.48 Million
0.219x +7.80%
2008-12-31 zł175.26 Million
≈ $48.23 Million
zł35.61 Million
≈ $9.80 Million
0.203x -59.73%
2007-12-31 zł166.62 Million
≈ $45.86 Million
zł84.07 Million
≈ $23.14 Million
0.505x +459.45%
2006-12-31 zł78.46 Million
≈ $21.59 Million
zł-11.01 Million
≈ $-3.03 Million
-0.140x -173.54%
2005-12-31 zł69.16 Million
≈ $19.03 Million
zł13.20 Million
≈ $3.63 Million
0.191x --

About Neuca S.A.

WAR:NEU Poland Medical Distribution
Market Cap
$879.55 Million
zł3.20 Billion PLN
Market Cap Rank
#9697 Global
#43 in Poland
Share Price
zł710.00
Change (1 day)
-1.80%
52-Week Range
zł649.00 - zł850.00
All Time High
zł953.88
About

NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company offers Rx, OTC drugs, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic an… Read more